ENTRY       D10018                      Drug
NAME        Necitumumab (USAN/INN);
            Necitumumab (genetical recombination) (JAN);
            Portrazza (TN)
PRODUCT     PORTRAZZA (Eli Lilly and Company)
SEQUENCE    (Heavy chain)
            QVQLQESGPG LVKPSQTLSL TCTVSGGSIS SGDYYWSWIR QPPGKGLEWI GYIYYSGSTD
            YNPSLKSRVT MSVDTSKNQF SLKVNSVTAA DTAVYYCARV SIFGVGTFDY WGQGTLVTVS
            SASTKGPSVL PLAPSSKSTS GGTAALGCLV KDYFPEPVTV SWNSGALTSG VHTFPAVLQS
            SGLYSLSSVV TVPSSSLGTQ TYICNVNHKP SNTKVDKRVE PKSCDKTHTC PPCPAPELLG
            GPSVFLFPPK PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY
            NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK ALPAPIEKTI SKAKGQPREP QVYTLPPSRE
            EMTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP VLDSDGSFFL YSKLTVDKSR
            WQQGNVFSCS VMHEALHNHY TQKSLSLSPG K
            (Light chain)
            EIVMTQSPAT LSLSPGERAT LSCRASQSVS SYLAWYQQKP GQAPRLLIYD ASNRATGIPA
            RFSGSGSGTD FTLTISSLEP EDFAVYYCHQ YGSTPLTFGG GTKAEIKRTV AAPSVFIFPP
            SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
            LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
            (Disulfide bridge: H22-H97, H148-H204, H224-L214, H230-H'230, H233-H'233, H265-H325, H371-H429, H'22-H'97, H'148-H'204, H'224-L'214, H'265-H'325, H'371-H'429, L23-L88, L134-L194, L'23-L'88, L'134-L'194)
  TYPE      Peptide
CLASS       Antineoplastic
             DG01918  Tyrosine kinase inhibitor
              DG01917  Receptor tyrosine kinase inhibitor
               DG03162  EGFR inhibitor
REMARK      Therapeutic category: 4291
            ATC code: L01FE03
            Product: D10018<JP/US>
EFFICACY    Antineoplastic, Receptor tyrosine kinase inhibitor, Anti-epidermal growth factor receptor antibody
  DISEASE   Squamous non-small cell lung cancer [DS:H00014]
  TYPE      Monoclonal antibody
TARGET      EGFR [HSA:1956] [KO:K04361]
  PATHWAY   hsa04010(1956)  MAPK signaling pathway
            hsa04012(1956)  ErbB signaling pathway
            hsa05223(1956)  Non-small cell lung cancer
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L01 ANTINEOPLASTIC AGENTS
               L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
                L01FE EGFR (Epidermal Growth Factor Receptor) inhibitors
                 L01FE03 Necitumumab
                  D10018  Necitumumab (USAN/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Antineoplastics
              Monoclonal Antibody/Antibody-Drug Conjugate
               Necitumumab
                D10018  Necitumumab (USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             4  Agents affecting cellular function
              42  Antineoplastics
               429  Miscellaneous
                4291  Other Antitumors
                 D10018  Necitumumab (USAN/INN); Necitumumab (genetical recombination) (JAN)
            Drug groups [BR:br08330]
             Antineoplastic
              DG01918  Tyrosine kinase inhibitor
               DG01917  Receptor tyrosine kinase inhibitor
                DG03162  EGFR inhibitor
                 D10018  Necitumumab
            Drug classes [BR:br08332]
             Antineoplastic
              DG03162  EGFR inhibitor
               D10018  Necitumumab
            Target-based classification of drugs [BR:br08310]
             Protein kinases
              Receptor tyrosine kinases (RTK)
               EGFR family
                EGFR
                 D10018  Necitumumab (USAN/INN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D10018
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D10018
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D10018
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D10018
DBLINKS     PubChem: 135626739
///
